Accelerate Diagnostics, Inc. (AXDX)

Market Cap	74.32M
Revenue (ttm)	13.12M
Net Income (ttm)	-70.50M
Shares Out	87.01M
EPS (ttm)	-1.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	295,236
Open	0.79
Previous Close	0.75
Day's Range	0.74 - 0.79
52-Week Range	0.5 - 5.59
Beta	1.24
Analysts	Buy
Price Target	2.04 (+171.1%)
Earnings Date	Nov 14, 2022

About AXDX

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic sus...

• Industry: Life Sciences Tools & Services
• IPO Date: Nov 18, 1996
• CEO: John Phillips
• Employees: 220
• Stock Exchange: NASDAQ
• Ticker Symbol: AXDX

Financial Performance

In 2021, AXDX's revenue was $11.78 million, an increase of 5.53% compared to the previous year's $11.17 million. Losses were -$77.70 million, -0.65% less than in 2020.

Analyst Forecast

According to 8 analysts, the average rating for AXDX stock is "Buy." The 12-month stock price forecast is 2.04, which is an increase of 171.06% from the latest price.

Price Target

$2.04

(171.06% upside)

Analyst Consensus: Buy